This site is intended for healthcare professionals

account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Biological therapies for rheumatoid arthritis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • biologic therapies include the tumour necrosis factor (TNF) alpha inhibitors, (etanercept, infliximab and adalimumab), rituximab and anakinra
  • NICE suggest that:
    • on the balance of its clinical benefits and cost effectiveness, anakinra is not recommended for the treatment of rheumatoid arthritis (RA), except in the context of a controlled, long-term clinical study
    • patients currently receiving anakinra for RA may suffer loss of wellbeing if their treatment were discontinued at a time they did not anticipate. Therefore, patients should continue therapy with anakinra until they and their consultant consider it is appropriate to stop
    • do not offer the combination of tumour necrosis factor- alpha inhibitor therapy and anakinra for RA

Reference:

  1. NICE (February 2009). Rheumatoid arthritis- The management of rheumatoid arthritis in adults

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.